Lydia Mapstone, PhD’s Post

An article highlighting Providence Research’s contributions to British Columbia’s growing ecosystem of biotechnology research is featured in the latest edition of BIOTECanada's Insights magazine, which is dedicated to showcasing the best of Canadian biotechnology. The spring issue of Insights showcases exclusive interviews with industry leaders, federal government perspectives, and ground-breaking research highlighting the dynamic landscape and future potential of Canada’s biotech sector. The article from Dr. Darryl Knight, President, Providence Research, covers the new Phase 1 Clinical Trials Unit at Mount Saint Joseph Hospital, and the consolidated Phase 1-3 Clinical Trials Unit that will be included at the Clinical Support and Research Centre at the new St. Paul’s Hospital. These state-of-the-art research facilities will serve a growing demand for non-cancer Phase 1 clinical trials in B.C., and foster collaboration between researchers, clinicians and industry experts to advance medical discovery. Read it here: https://lnkd.in/gr9KEd_C #research #healthcare #healthresearch #clinicaltrials #innovation #biotech #biotechnology

Vancouver, BC's thriving life sciences sector is set to receive a significant enhancement thanks to federal support. The government is allocating $140 million to four projects in British Columbia as part of establishing "Canada’s Immuno-Engineering and Biomanufacturing Hub." This funding is a segment of a broader $574 million initiative aimed at bolstering 19 projects across five research hubs nationwide under Canada’s #biomanufacturing and #lifesciences strategy. This investment will empower local medical researchers to transition their discoveries into startup ventures, further invigorating the region's biotechnological advancements. https://lnkd.in/g-ps4Gbf

✴ BGN's Bio Team shines at the Biomed Israel 2024 We had a strong presence at the recent Biomed Israel 2024 conference in Tel Aviv. Our bio team Galit Mazooz - Perlmuter 🎗 Ph.D Hagit Alon, (PhD) Micha Oestereich showcased cutting-edge technologies from Ben-Gurion University researchers and engaged in a whirlwind of activities. Our team had personal discussions with leading biotech and pharmaceutical companies, entrepreneurs who are seeking to adopt new technologies, venture capitalists, and industry colleagues. Conversations focused on potential collaborations, partnerships, and pathways to commercialize BGN's innovative biomedical technologies. The team also connected with existing partners like Magneto Thrombectomy Solutions, and OncoRedox Ltd., companies licensed by BGN .🤝 The goal was to drive innovation by facilitating the integration of Ben-Gurion's groundbreaking research into products and therapies. Through these meetings and networking opportunities, we took strides toward assimilating the university's biomedical breakthroughs into the broader life sciences industry. All in all, the Biomed Israel 2024 was a great opportunity to explore promising opportunities for Ben-Gurion's biomedical technologies. Josh Peleg #Biomed2024 #Biopharma #bioinnovation #Biotech

🔎Considering investing in the European region, is the UK an attractive place for Life Sciences? Discover some insights ahead of 2024 #Biotrinity UK and #LSX World Congress next month in London. In 2023 alone, UK biotechs attracted an estimated £8.2 billion through licensing agreements, with significant M&A activity highlighting the sector's vibrancy and potential for lucrative partnerships. 💸 ⌚The UK's NHS Innovation Accelerator and initiatives like ILAP and Project Orbis accelerate the path from breakthrough ideas to real-world solutions, particularly in cancer treatment. 🧬Home to the UK Innovation Hub and world-renowned academic networks, the UK is a nexus of pharmaceutical, medical devices, and health tech advancements, driving forward with AI, CRISPR, and pioneering therapeutic approaches. Opting for the UK grants access to an ecosystem rich in support, where innovation thrives across various fields, from pioneering T-regulatory cell therapies to the frontiers of AI in drug discovery. Here, companies benefit from a robust academic landscape, ample funding options, and a government dedicated to pushing health technology forward. For a peek at the insights shared, or to get the full presentation, email us at [email protected]. #ukinnovation #investment #NHS #biotech

Ontario’s #lifesciences sector is world-renowned, with competitive advantages in R&D and pharmaceuticals to the manufacturing of clinical devices and biotechnology innovations. That’s why through Phase 2 of “Taking Life Sciences to the Next Level”, we are investing $146M to continue growing the sector, by: ☑️ Boosting research capacity ☑️ Increasing access to lab space ☑️ Speeding up health trials ☑️ Launching modernized procurement processes and ☑️ Establishing new funds

This Globe and Mail article, by Sean Silcoff, is a who's who of the B.C. life sciences sector and a great overview of what's happening in the province now. Here are some highlights: “I want to build a $100-billion company, but it has to be here, it can be here, and it will be here,” says Tamer Mohamed, chief executive officer of Aspect Biosystems, which occupies QLT’s former home and whose cutting-edge approach to curing diabetes landed it on Fast Company’s 2023 “Next Big Things in Tech” list. “To get there we have to be a bit un-Canadian about it.” Aspect is a CCRM portfolio company. Vancouver is already Canada’s fastest-growing biotech centre, with 8,000 jobs added over the past 10 years, up to nearly 20,000, while the number of businesses in B.C. grew by 26.5 per cent from 2018 to 2021. “Vancouver probably has the critical mass of talent, companies, capital and technology to put it in the top 10 globally" of biotech centres despite lacking Toronto and Montreal’s Big Pharma branch locations, says Brian Bloom, CEO of Toronto life sciences underwriter Bloom Burton & Co. cc: Peter Zandstra, Abi Coman-Walker, STEMCELL Technologies, Jerel Davis https://lnkd.in/gnZYptpE

𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐨𝐟 𝐀𝐓𝐌𝐏𝐬: 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐂𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐭𝐡𝐞 𝐃𝐮𝐭𝐜𝐡 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 🌟 Why do ATMPs, with their transformative potential, still struggle to gain traction? On December 12th, I will host a session titled "Cell Therapy: The Investment Landscape and Clinical Insights" at the Dutch Life Sciences conference in Leiden, where we’ll delve into this critical question.👩🔬 I’ll be joined by experts from life sciences financing, ATMP CMC manufacturing, and academic regulatory effectiveness to explore: 💰 Why cell therapy is viewed as high-risk by investors despite its groundbreaking clinical promise. 🌍 Key trends shaping global financing for life sciences, with a focus on ATMPs. ⚙️ Technical and logistical hurdles to scaling ATMP production while safeguarding quality. 🤝 Opportunities for academia, industry, and regulators to collaborate and resolve bottlenecks in clinical trials and approvals. 📊 Did you know that medicines in general are approximately 2.2 times more likely to achieve Marketing Authorization (MA) success compared to ATMPs (1)? This disparity highlights the unique hurdles ATMPs face despite their immense therapeutic potential. From my experience, challenges like high Cost-of-Goods, limited multipurpose cleanroom capacity, small batch numbers, low yield, and contamination risks often weigh down ATMP manufacturing. Add to this the stress on project managers juggling these complexities. 💡  𝐖𝐡𝐚𝐭 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐡𝐚𝐯𝐞 𝐲𝐨𝐮 𝐬𝐞𝐞𝐧 𝐰𝐨𝐫𝐤 𝐭𝐨 𝐚𝐝𝐝𝐫𝐞𝐬𝐬 𝐭𝐡𝐞𝐬𝐞 𝐛𝐚𝐫𝐫𝐢𝐞𝐫𝐬? Share your thoughts in the comments or connect with me—I’d love to discuss solutions and ideas! Ref.1: https://lnkd.in/dAsfAmQy Program: https://lnkd.in/d4WtKX8J Speakers: Jan De Kerpel, Chantal van Litsenburg, Frank van Engelenburg #ATMPs #CellTherapy #LifeSciences #Innovation 🚀

Come join us in Boston in October to talk about AI in Drug Discovery! I'll be presenting on some of the latest techniques in protein diffusion. Plus, you'll see how I design and test targeted antibodies, all "in silico". (Also, there's still time to submit an abstract.) #ai #drugdiscovery #precisionmedicine #antibodies #drugdesign #pharma #healthcare #bioinformatics #computationalbiology #datascience #genetics #genomics 🧬🐖💊

https://lnkd.in/dsnbsfD4 The Rising Need for an Integrated Approach to Small Molecules Drug Development: Julian Northen, PhD, believes as the demands of a changing society evolve and continue to act as a driver for the identification of novel small molecules, the roles and diversity of the available medicines will also change.

So Many Conferences — So Little Time: Which Conference to Visit? I often get asked by companies and industry stakeholders which conferences they should visit or which are worth attending in the first half of the year. I have been in the circle for 25 years now and there is no straight answer. The standard response is, it depends on what you are looking for. If you are looking for general partnering, there are a number of big conferences like the "BIO International Convention" and "#bioeuropespring ", where you can meet people from all over the world. However, there are also some (smaller) regional-focused conferences like the "Swiss Biotech Day #swissbiotechday", which has grown to over 1,800 participants, or the "Asia Bio Partnering Forum #ASIABIO" and "BIO KOREA". There are also therapeutic or technology-focused conferences like "Advanced Therapies" in London, "Festival of Biologics" in San Diego, or "The World Vaccine Congress" in DC. If you are fundraising, there are options like the "BIO CEO & Investor Conference" in NY for more mature (public) companies, "RESI Conferences Life Science Nation (LSN)" (Atlanta and Barcelona) for earlier stage (private) companies, as well as "LSX World Congress" in London or "The Annual European Life Sciences CEO Forum #Sachs_ELSF" in Zurich. Additionally, different investment banks host conferences, of which "JPM JPMorgan Chase & Co." in San Francisco is where the industry meets. For very intimate interactions with other Biotech CEOs, I can recommend the "Biotech CEO Summit CEO Summit by Demy-Colton" in Barcelona and La Jolla. You can find all these conferences, along with their dates and links here » https://lnkd.in/dawnkF6p